NCT07262970 2025-12-04
Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a Tumor
Rezolute
Available
Clinical Trials
7 trialsNCT04814732 2024-04-12
Expanded Access Program of Surufatinib
Hutchmed
No longer available
NCT04334837 2020-10-09
Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs)
Curium US LLC
Approved for marketing
NCT02174679 2020-07-27
68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)
Jonsson Comprehensive Cancer Center
No longer available
NCT02705313 2018-04-09
EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx
Advanced Accelerator Applications
Approved for marketing
NCT02375464 2016-11-08
Gallium-68 DOTATOC for Management of Neuroendocrine Tumors
Northwell Health
No longer available
NCT02358018 2016-11-02
68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial
Memorial Sloan Kettering Cancer Center
No longer available